Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022)

(1) Background: With the massive demand for the use and commercialization of medicinal cannabidiol (CBD) products, new randomized clinical trials (RCTs) are being published worldwide, with a constant need for safety and efficacy evaluation. (2) Methods: We performed an update on a systematic review...

Descripción completa

Detalles Bibliográficos
Autores principales: Souza, José Diogo R., Pacheco, Julia Cozar, Rossi, Giordano Novak, de-Paulo, Bruno O., Zuardi, Antonio W., Guimarães, Francisco S., Hallak, Jaime E. C., Crippa, José Alexandre, Dos Santos, Rafael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782576/
https://www.ncbi.nlm.nih.gov/pubmed/36559092
http://dx.doi.org/10.3390/pharmaceutics14122598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782576/
https://www.ncbi.nlm.nih.gov/pubmed/36559092
http://dx.doi.org/10.3390/pharmaceutics14122598

Ejemplares similares